Trial Profile
Third-line therapy with apatinib in metastatic colorectal cancer: individualized dose adjustment based on plasma concentration and adverse reactions
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 07 Mar 2018 New trial record